Fairmount Funds Management LLC
- SEC CIK
- 0001802528
- Latest filing
- Aug 14, 2026
Holdings in Q2 2025
Holdings as of Jun 30, 2025, filed Aug 14, 2025. Long positions only; changes compare share counts with Q1 2025.
- Positions
- 17
- +2 vs. Q1 2025
- Portfolio value
- $771.9M
- +$127.3M (+19.7%) vs. Q1 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| APGEApogee Therapeutics, Inc. | COM | 2,048,647 | $89.0M | 11.5% | 00.0% | Unchanged | History |
| AXSMAxsome Therapeutics, Inc. | COM | 815,176 | $85.1M | 11.0% | 00.0% | Unchanged | History |
| ELVNEnliven Therapeutics, Inc. | COM | 3,711,444 | $74.5M | 9.6% | +508,646+15.9% | Added | History |
| SRRKScholar Rock Holding Corp | COM | 1,824,031 | $64.6M | 8.4% | +450,000+32.8% | Added | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 4,018,101 | $60.2M | 7.8% | 00.0% | Unchanged | History |
| NUVLNuvalent, Inc. | COM | 727,563 | $55.5M | 7.2% | 00.0% | Unchanged | History |
| DNTHDianthus Therapeutics, Inc. | COM | 2,707,191 | $50.4M | 6.5% | +6,500+0.2% | Added | History |
| KNSAKiniksa Pharmaceuticals International, plc | ORD SHS CL A | 1,772,839 | $49.1M | 6.4% | +670,591+60.8% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 3,459,913 | $48.4M | 6.3% | +14,100+0.4% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 6,225,641 | $44.7M | 5.8% | 00.0% | Unchanged | History |
| ORKAOruka Therapeutics, Inc. | COM | 3,371,922 | $37.8M | 4.9% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM NEW | 3,220,368 | $32.2M | 4.2% | +3,220,368 | New | History |
| CBIOCrescent Biopharma, Inc. | COM | 1,387,866 | $22.4M | 2.9% | +1,387,866 | New | History |
| ATXSAstria Therapeutics, Inc. | COM | 3,554,129 | $19.1M | 2.5% | 00.0% | Unchanged | History |
| ZBIOZenas BioPharma, Inc. | COM | 1,892,806 | $18.3M | 2.4% | 00.0% | Unchanged | History |
| IKTInhibikase Therapeutics, Inc. | COM NEW | 6,125,000 | $11.9M | 1.5% | 00.0% | Unchanged | History |
| CTMXCytomX Therapeutics, Inc. | COM | 3,896,582 | $8.85M | 1.1% | +3,896,582 | New | History |
Sold out since Q1 2025 (1)
Positions held at the end of Q1 2025 that are gone from this filing.